WHO SMART Guidelines - Example Workshop IG
0.1.0 - ci-build
WHO SMART Guidelines - Example Workshop IG, published by WHO. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/brynrhodes/smart-workshop/ and changes regularly. See the Directory of published versions
| Official URL: http://smart.who.int/example-workshop/PlanDefinition/IMMZD2DTMeaslesSupplementary | Version: 0.1.0 | |||
| Draft as of 2024-12-02 | Computable Name: IMMZD2DTMeaslesSupplementary | |||
If the child or patient has not been given a supplementary dose
Generated Narrative: PlanDefinition IMMZD2DTMeaslesSupplementary
CQF Knowledge capability: computable
url: PlanDefinition IMMZ.D2.DT.Measles MCV Dose 0
version: 0.1.0
name: IMMZD2DTMeaslesSupplementary
title: IMMZ.D2.DT.Measles MCV Dose 0
type: ECA Rule
status: Draft
experimental: true
date: 2024-12-02 20:41:15+0000
publisher: WHO
contact: WHO: http://who.int
description:
If the child or patient has not been given a supplementary dose
| Type | Citation |
| Citation | WHO recommendations for routine immunization - summary tables (March 2023) |
library: IMMZD2DTMeaslesSupplementaryLogic
action
title: Immunize patient for Measles
condition
kind: Applicability
Expressions
Language Expression text/cql-identifier Measles Routine Immunization Schedule Complete action
CPG Rationale Extension:
An additional dose of MCV should be administered to HIV-infected children receiving HAART following immune reconstitution. If CD4+ T lymphocyte counts are monitored, an additional dose of MCV should be administered when immune reconstitution has been achieved, e.g. when the CD4+ T lymphocyte count reaches 20–25%. Where CD4+ T lymphocyte monitoring is not available, children should receive an additional dose of MCV 6–12 months after initiation of HAART.<br/>As a general rule, live vaccines should be given either simultaneously or at intervals of 4 weeks. An exception to this rule is OPV, which can be given at any time before or after measles vaccination without interference in the response to either vaccine
title: Consider supplementary dose
condition
kind: Applicability
Expressions
Language Expression text/cql-identifier No Supplementary Dose Administered action
title: Last Live Vaccine Administered Within 4 Weeks
description: Should not vaccinate client for measles supplementary dose as live vaccine was administered in the last 4 weeks. Check for any vaccines due, and inform the caregiver of when to come back for supplementary dose.
condition
kind: Applicability
Expressions
Language Expression text/cql-identifier Last Live Vaccine Administered Within 4 Weeks action
title: Provide Measles Vaccine
description: May vaccinate client for measles supplementary dose as supplementary dose was not administered, measles routine immunization schedule is complete and no live vaccine administered in the last 4 weeks. Check if one of the measles supplementary dose specific scenarios is applicable.
condition
kind: Applicability
Expressions
Language Expression text/cql-identifier Client Is Due For Supplementary Dose definition: IMMZ.D2.DT.Measles.MR
dynamicValue
path: dispenseRequest.validityPeriod.start
Expressions
Description Language Expression Due date of the dose text/cql-identifier MCV Supplementary Schedule Date dynamicValue
path: dispenseRequest.validityPeriod.end
Expressions
Description Language Expression Expiration date for MCV dose text/cql-identifier MCV Supplementary Expiration Date action
title: Supplementary Dose Administered
description: Measles immunization schedule is complete. Measles supplementary dose was administered.
condition
kind: Applicability
Expressions
Language Expression text/cql-identifier Supplementary Dose Administered